- Wainberg, Z. A., Van Cutsem, E., Götze, T., Sendur, M. A. N., Al-Farhat, Y., Wysocki, P. J., Mansoor, W., Bitzer, M., Skoropad, V., Rey, F., Oh, D.-Y., Liberman, M., Molena, D., Muro, K., Hyung, W. J., Cheng, L.-Y., Hernandorena, F., Robbins, S., Janjigian, Y. Y., & Tabernero, J. (2026). Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (Flot) chemotherapy in resectable gastric/gastroesophageal junction (G/gej) cancer. Journal of Clinical Oncology, 44(16_suppl), 4070-4070. https://doi.org/10.1200/JCO.2026.44.16_suppl.4070 (Meeting abstract)
Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (Flot) chemotherapy in resectable gastric/gastroesophageal junction (G/gej) cancer
on 19 d'octubre de 2026
with No hi ha comentaris
Deixa un comentari